Nothing Special   »   [go: up one dir, main page]

BRPI0514470A - 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2, 4-diona e análogos como inibidores de elastase macrofágica - Google Patents

5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2, 4-diona e análogos como inibidores de elastase macrofágica

Info

Publication number
BRPI0514470A
BRPI0514470A BRPI0514470-1A BRPI0514470A BRPI0514470A BR PI0514470 A BRPI0514470 A BR PI0514470A BR PI0514470 A BRPI0514470 A BR PI0514470A BR PI0514470 A BRPI0514470 A BR PI0514470A
Authority
BR
Brazil
Prior art keywords
benzyloxyphenylthio
fur
dione
imidazolin
macrophage elastase
Prior art date
Application number
BRPI0514470-1A
Other languages
English (en)
Inventor
Fude Yang
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Publication of BRPI0514470A publication Critical patent/BRPI0514470A/pt
Publication of BRPI0514470B1 publication Critical patent/BRPI0514470B1/pt
Publication of BRPI0514470B8 publication Critical patent/BRPI0514470B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

5- ¢3- (4-BENZILOXIFENILTIO) -FUR-2-IL! -IMIDAZOLIN-2,4-DIONA E ANáLOGOS COMO INIBIDORES DE ELASTASE MACROFáGICA 5-{ ¢3- (4-benziloxifeniltio) -fur-2-il! }-imidazolin-2,4-diona e análogos úteis como inibidores de elastase macrofágica são revelados.
BRPI0514470A 2004-08-19 2005-08-17 composto 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2,4-diona e composição farmacêutica BRPI0514470B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
US60/602.736 2004-08-19
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (3)

Publication Number Publication Date
BRPI0514470A true BRPI0514470A (pt) 2008-06-10
BRPI0514470B1 BRPI0514470B1 (pt) 2021-01-05
BRPI0514470B8 BRPI0514470B8 (pt) 2021-07-20

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514470A BRPI0514470B8 (pt) 2004-08-19 2005-08-17 composto 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2,4-diona e composição farmacêutica

Country Status (17)

Country Link
US (1) US7179831B2 (pt)
EP (1) EP1789036B1 (pt)
JP (1) JP5042833B2 (pt)
KR (1) KR101197325B1 (pt)
CN (1) CN101014338B (pt)
AT (1) ATE508744T1 (pt)
AU (1) AU2005277432B2 (pt)
BR (1) BRPI0514470B8 (pt)
CA (1) CA2577430C (pt)
DK (1) DK1789036T3 (pt)
ES (1) ES2364068T3 (pt)
HK (1) HK1107774A1 (pt)
MX (1) MX2007001940A (pt)
NZ (1) NZ553258A (pt)
RU (1) RU2391339C2 (pt)
SI (1) SI1789036T1 (pt)
WO (1) WO2006023562A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2636990A1 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Animal model for assessing copd-related diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
PT3503885T (pt) * 2016-08-19 2022-04-19 Foresee Pharmaceuticals Co Ltd Composição farmacêutica e métodos de utilização
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
ES2865854T3 (es) * 2016-09-23 2021-10-18 Kaken Pharma Co Ltd Método para producir (r)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidin-2,4-diona y un producto intermedio para producir la misma
CN112424192A (zh) * 2018-05-15 2021-02-26 逸达生物科技美国公司 基质金属蛋白酶(mmp)抑制剂及其应用方法
US20230014855A1 (en) * 2019-11-14 2023-01-19 Foresee Pharmaceuticals, Co., Ltd. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
CA3217780A1 (en) * 2021-06-08 2022-12-15 Benjamin Chien Safe administration of mmp-12 inhibitor
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
EP1150975A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7041693B2 (en) * 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)

Also Published As

Publication number Publication date
AU2005277432B2 (en) 2011-11-24
HK1107774A1 (en) 2008-04-18
CA2577430A1 (en) 2006-03-02
WO2006023562A2 (en) 2006-03-02
ES2364068T3 (es) 2011-08-24
BRPI0514470B1 (pt) 2021-01-05
BRPI0514470B8 (pt) 2021-07-20
EP1789036A4 (en) 2008-08-27
JP5042833B2 (ja) 2012-10-03
WO2006023562A3 (en) 2006-04-20
EP1789036B1 (en) 2011-05-11
KR101197325B1 (ko) 2012-11-05
MX2007001940A (es) 2007-07-24
SI1789036T1 (sl) 2011-09-30
AU2005277432A1 (en) 2006-03-02
WO2006023562B1 (en) 2006-06-22
EP1789036A2 (en) 2007-05-30
US20060041000A1 (en) 2006-02-23
RU2007105822A (ru) 2008-09-27
NZ553258A (en) 2011-02-25
ATE508744T1 (de) 2011-05-15
CN101014338B (zh) 2010-06-16
RU2391339C2 (ru) 2010-06-10
CN101014338A (zh) 2007-08-08
DK1789036T3 (da) 2011-06-27
JP2008510701A (ja) 2008-04-10
CA2577430C (en) 2010-12-07
US7179831B2 (en) 2007-02-20
KR20070045330A (ko) 2007-05-02

Similar Documents

Publication Publication Date Title
HK1107774A1 (en) 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ;
NO20080622L (no) Disykloalkylurea-glukokinase aktivatorer
DK2468732T3 (da) 1H-Quinazolin-2,4-dioner
NO20053161D0 (no) Mikrobedrepende sammensetning.
EA200701918A1 (ru) Белок липокалин
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
ATE510822T1 (de) Kaliumkanalinhibitoren
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE527362T1 (de) Verbesserte expression zeigendemodifizierte xylanasen
FI20041419A0 (fi) Soodakattilan keon hallinta
BRPI0719836A2 (pt) Clonagem, expressão e uso de fosfolipases ácidas.
AR059544A1 (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas
BRPI0816810A2 (pt) utilização de pelo menos um composto, e, composto.
NO20081069L (no) Dynamisk, anvendelsesutvidende teknologi
FR2878980B1 (fr) Unite de retro-eclairage de type direct.
ES1058780Y (es) Brida de union autoblocante.
ES1056879Y (es) Plomada laser.
ES1059759Y (es) Multibolsa de basura.
ES1058173Y (es) Viga de poliuretano chapada.
ES1058482Y (es) Disposicion de timoneria de paracaidas de ascensor.
ES1057865Y (es) Desatascador de desagues.
ES1060365Y (es) Frigorifico partido.
ITFR20040018A1 (it) Antislavina & i.s.m.
ES1061049Y (es) Estanteria-libreria con puertas de persiana.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FORESEE PHARMACEUTICALS, CO., LTD. (CN)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO AO DESENHO E O RESUMO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2683 DE 07-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.